BGM Group (BGM) SEC Filings: History & Chart

BGM Group Ltd.(BGM)

Drug Manufacturers - Specialty & Generic · Chengdu, SIC

$8.82-0.54 (-5.72%)

Delayed quote: Oct 6, 2026, 10:20 AM EDT

About BGM Group Ltd.

Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers. Beyond APIs, the company produces TCM derivatives such as Ahan antibacterial paste, which is designed for managing stubborn chronic skin conditions. Its diverse offerings also encompass heparin products, including heparin sodium preparations essential for pharmaceutical companies developing treatments for cardiovascular and cerebrovascular diseases, as well as hemodialysis applications. Furthermore, BGM supplies natural food products like Zhu Xiaochang sausage casings for culinary use. In the agricultural sector, it offers Xiongguan organic fertilizers, which enhance crop yields, improve soil chemical characteristics, and alleviate compaction, alongside Xiongguan organic-inorganic compound fertilizers engineered to promote superior plant development. Established in 2019, the company operated as Qilian International Holding Group Limited until adopting its current name, BGM Group Ltd, in October 2024.

Chengdu, SIC

298 employees

www.bgmgroupltd.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Chen Xin

View full financials

Form	Filing Date	Accepted	Document
6-K	May 18, 2026	May 18, 2026	View filing
3	May 14, 2026	May 15, 2026	View filing
3	May 14, 2026	May 15, 2026	View filing
3	May 14, 2026	May 15, 2026	View filing
3	May 14, 2026	May 15, 2026	View filing
6-K	May 7, 2026	May 7, 2026	View filing
6-K	Apr 30, 2026	Apr 30, 2026	View filing
3	Apr 13, 2026	Apr 13, 2026	View filing
NT 20-F	Jan 30, 2026	Jan 30, 2026	View filing
6-K	Jan 29, 2026	Jan 29, 2026	View filing
6-K	Dec 22, 2025	Dec 22, 2025	View filing
6-K	Aug 14, 2025	Aug 14, 2025	View filing
6-K	Jul 24, 2025	Jul 24, 2025	View filing
6-K	Jun 26, 2025	Jun 26, 2025	View filing
S-8	Jun 3, 2025	Jun 3, 2025	View filing
6-K	May 28, 2025	May 28, 2025	View filing
SC 13G	May 28, 2025	May 28, 2025	View filing
SC 13G	May 28, 2025	May 28, 2025	View filing
SC 13D/A	May 27, 2025	May 27, 2025	View filing
SC 13D	May 27, 2025	May 27, 2025	View filing
UPLOAD	May 20, 2025	May 20, 2025	View filing
6-K	May 20, 2025	May 20, 2025	View filing
CORRESP	May 8, 2025	May 8, 2025	View filing
20-F/A	May 8, 2025	May 8, 2025	View filing
6-K	May 6, 2025	May 6, 2025	View filing
SC 13G	May 6, 2025	May 6, 2025	View filing
SC 13G	May 6, 2025	May 6, 2025	View filing
6-K	Apr 28, 2025	Apr 28, 2025	View filing
UPLOAD	Apr 25, 2025	Apr 25, 2025	View filing
6-K	Apr 22, 2025	Apr 22, 2025	View filing

SEC Filings

Recent Filings